News &amp; Updates

Use of an oral herbal supplement appears to be more favourable than oestrogen plus progestogen therapy in terms of reducing global, physical, and psychosocial menopausal symptoms in the short term, according to a phase II study.

Oral herbal supplement bests estrogen plus progestogen therapy for menopausal symptoms

Canagliflozin holds promise against MAFLD in T2D patients

27 Oct 2023 by

Patients with type 2 diabetes (T2D) who received canagliflozin benefit from improved liver biochemistry and metabolism, a recent study has shown. In addition, treatment with canagliflozin appears to confer positive effects on liver fibrosis.

Canagliflozin holds promise against MAFLD in T2D patients

27 Oct 2023

Ivarmacitinib efficacious, well tolerated in moderate-to-severe alopecia areata

Use of ivarmacitinib 4- and 8-mg doses for 24 weeks eases hair loss and is generally tolerated in patients with moderate or severe alopecia areata (AA), a phase II study has shown.

Ivarmacitinib efficacious, well tolerated in moderate-to-severe alopecia areata

27 Oct 2023

4-hydroxytamoxifen gel strikes out in ductal carcinoma in situ lesions

Local transdermal therapy with 4-hydroxytamoxifen appears to be less effective than full-dose oral tamoxifen in terms of suppressing proliferation in ductal carcinoma in situ lesions for breast cancer prevention, according to a phase II study.

4-hydroxytamoxifen gel strikes out in ductal carcinoma in situ lesions

COVID-19 vax in pregnancy not linked to adverse newborn, early infant outcomes

Receipt of mRNA COVID-19 vaccination during pregnancy does not appear to increase the incidence of adverse newborn and early infant outcomes and may even be protective, according to a study.

COVID-19 vax in pregnancy not linked to adverse newborn, early infant outcomes

Ritonavir-boosted nirmatrelvir protects older adults against post-COVID conditions

Treatment with nirmatrelvir/ritonavir helps lower the incidence of post-COVID conditions (PCC) in older adults, according to a large study.

Ritonavir-boosted nirmatrelvir protects older adults against post-COVID conditions

Brentuximab vedotin fares well for CTCL in real-world study

Interim findings from a prospective real-world study in Poland demonstrated favourable clinical outcomes and a tolerable safety profile for the CD30-directed antibody-drug conjugate brentuximab vedotin in patients with CD30-expressing cutaneous T-cell lymphoma (CTCL).

Brentuximab vedotin fares well for CTCL in real-world study

One BPG dose may be enough to treat syphilis, regardless of HIV status

Three doses of benzathine penicillin G (BPG) are not necessarily better than a single dose in the treatment of early syphilis in individuals with or without HIV infection, as shown in a study.

One BPG dose may be enough to treat syphilis, regardless of HIV status

26 Oct 2023

mRNA-1647 vaccine well tolerated regardless of CMV serostatus

MRNA-1647, Moderna's investigational mRNA-based vaccine against cytomegalovirus (CMV), is well tolerated in healthy adults regardless of CMV serostatus, according to a study presented at IDWeek 2023.

mRNA-1647 vaccine well tolerated regardless of CMV serostatus